Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM7 | Q14831 | 3/20 | 0.44 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.39 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | MME | P08473 | 1/20 | 0.36 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12966499 | 1.00 | GRM7 (0.44) | GRM7MTNR1AMTNR1BHRH3MME | |
| SCHEMBL17995302 | 0.89 | MTNR1A (0.48) | GRM7MTNR1AMTNR1BNPY5RLMNA | |
| SCHEMBL10442380 | 0.86 | MTNR1A (0.42) | GRM7MTNR1AMTNR1BHRH3MAPT | |
| SCHEMBL14898401 | 0.86 | MTNR1A (0.42) | GRM7MTNR1AMTNR1BHRH3MAPT | |
| SCHEMBL10442065 | 0.86 | MTNR1A (0.42) | GRM7MTNR1AMTNR1BHRH3MAPT | |
| SCHEMBL14979998 | 0.84 | GRM7 (0.41) | GRM7MTNR1AMTNR1BHRH3MAPT | |
| SCHEMBL14025206 | 0.82 | GRM7 (0.41) | GRM7MTNR1AMTNR1BHRH3MAPT | |
| SCHEMBL21508992 | 0.82 | GRM7 (0.41) | GRM7MTNR1AMTNR1BOPRM1OPRD1 | |
| SCHEMBL27923521 | 0.80 | GRM7 (0.40) | GRM7MTNR1AMTNR1BNPY5ROPRM1 | |
| SCHEMBL239019 | 0.80 | GRM7 (0.40) | GRM7MTNR1AMTNR1BNPY5ROPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120071329-A1 | METHODS FOR IDENTIFYING COMPOUNDS OF INTEREST USING ENCODED LIBRARIES | GLAXOSMITHKLINE LLC (US) | 2012-03-22 | — | — | US | disclosed |
| US-20110251089-A1 | METHODS FOR SYNTHESIS OF ENCODED LIBRARIES | GLAXOSMITHKLINE (US) | 2011-10-13 | — | — | US | disclosed |
| US-7989395-B2 | Methods for identifying compounds of interest using encoded libraries | GLAXOSMITHKLINE LLC (US) | 2011-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251089-A1 | METHODS FOR SYNTHESIS OF ENCODED LIBRARIES | RNGTT, DTYMK, DUT | GRM7 3030/4885MTNR1A 3336/4885MTNR1B 2986/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.